Medigene AG (MDGEF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Medigene AG (MDGEF) Healthcare & Pipeline Overview

Medigene AG is a German biotechnology firm specializing in T-cell immunotherapies for cancer, including TCR-modified T cells, aimed at addressing significant unmet medical needs. The company is in clinical development, also researching dendritic cell vaccines and T-cell-specific antibodies, with strategic partnerships across global markets.

What Is the Investment Thesis for MDGEF?

Medigene AG presents an investment profile centered on its innovative T-cell immunotherapy platform, particularly its T-cell receptor (TCR)-modified T cell therapies, which are in clinical development for cancer treatment. The company addresses a significant unmet medical need within oncology, a market with substantial growth potential. Strategic partnerships with entities like 2seventy bio, Inc., Université de Montréal, and Cytovant Sciences Co. Ltd. provide external validation and resource leverage for its research and development efforts. However, as a development-stage biotechnology firm with a market capitalization of $38.2M and a profit margin of -268.1%, Medigene faces inherent clinical and regulatory risks associated with bringing novel therapies to market. Success hinges on positive clinical trial outcomes, regulatory approvals, and sustained funding. The company’s gross margin of 72.8% suggests efficient management of its current revenue streams, likely from partnerships, but future profitability depends on successful product commercialization. Investors monitor pipeline progress and partnership developments closely.

Based on FMP financials and quantitative analysis

MDGEF Key Highlights

Medigene AG operates with a market capitalization of $38.2M, reflecting its status as a development-stage biotechnology firm.

• The company reported a profit margin of -268.1%, indicative of significant ongoing research and development expenditures typical for a clinical-stage biotech.
• A gross margin of 72.8% suggests effective cost management relative to its current revenue, likely derived from collaboration agreements and licensing activities.
• Medigene AG employs 87 individuals, focusing its human capital on specialized biotechnology research and clinical development.
• The stock exhibits a Beta of 1.36, indicating higher volatility compared to the broader market, which is common for smaller, development-stage biotechnology companies.

Who Are MDGEF's Competitors?

MDGEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDGEF's Key Strengths?

Innovative T-cell receptor (TCR)-modified T cell platform addressing high unmet medical needs in oncology.

• Strategic partnerships with established biotech firms (e.g., 2seventy bio) and research institutions.
• Diversified pipeline including dendritic cell vaccines, T-cell-specific monoclonal antibodies, and RhuDex.
• Global operational reach with activities in Europe, US, and Asia.
• High gross margin of 72.8%, indicating efficient management of current revenue streams.

What Are MDGEF's Weaknesses?

Development-stage company with a negative profit margin of -268.1%, indicating significant losses.

• Small market capitalization of $38.2M, potentially limiting access to capital.
• Reliance on clinical trial success and regulatory approvals for future commercial viability.
• Trades on the OTC market, which may imply lower liquidity and transparency.
• Limited commercial products currently generating substantial revenue.

What Could Drive MDGEF Stock Higher?

MDGEF catalyst: Announcement of clinical trial data readouts for its T-cell receptor (TCR)-modified T cell therapies, which could significantly impact valuation.

• Achievement of regulatory milestones, such as Fast Track designation or progression to later-stage clinical trials, for its lead immunotherapy candidates.
• Formation of new strategic partnerships or expansion of existing collaborations, potentially bringing in additional non-dilutive funding or expertise.
• Progress in the development and potential commercialization pathway for RhuDex in hepatology and gastroenterology indications.
• Continued advancement of its research pipeline for dendritic cell vaccines and T-cell-specific monoclonal antibodies, broadening future therapeutic options.

What Are the Key Risks for MDGEF?

Financial-distress signal — its Altman Z-Score of -23.79 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-55.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High clinical trial failure rates inherent in biotechnology, where many experimental therapies do not reach market approval.
• Significant capital requirements for research and development, potentially leading to future equity dilution through fundraising.
• Intense competition from larger pharmaceutical companies and other well-funded biotech firms in the immuno-oncology space.
• Regulatory hurdles and lengthy approval processes for novel cell and gene therapies, extending time to market and increasing costs.
• Negative profit margin of -268.1%, indicating the company is not yet profitable and relies on external funding to sustain operations.

What Are the Growth Opportunities for MDGEF?

• Growth opportunity 1: Advancement of the TCR-T Pipeline. Medigene's core focus on T-cell receptor (TCR)-modified T cells for cancer treatment represents a significant growth driver. Successful progression through clinical trial phases, particularly achieving positive efficacy and safety data in later-stage trials, could unlock substantial value. Each successful clinical milestone, such as entering Phase 2 or Phase 3, or receiving regulatory designations, enhances the therapy's commercial potential and attracts further investment or partnership opportunities.
• Growth opportunity 2: Strategic Partnerships and Collaborations. Medigene's existing partnerships with 2seventy bio, Inc., Université de Montréal, and Cytovant Sciences Co. Ltd. are crucial for leveraging external expertise and resources. Expanding these collaborations or forming new ones with larger pharmaceutical companies could provide significant non-dilutive funding, access to broader research capabilities, and global commercialization infrastructure. Such partnerships can accelerate drug development, reduce financial risk, and broaden market reach. The value of biotech partnerships often involves upfront payments, milestone payments tied to development progress, and royalties on future sales, providing a stable revenue stream for a development-stage company.
• Growth opportunity 3: Diversification into Other Immunotherapy Modalities. Beyond TCR-T cells, Medigene's engagement in researching and developing dendritic cell vaccines and T-cell-specific monoclonal antibodies offers additional avenues for growth. Success in these areas could broaden the company's therapeutic portfolio and address different patient populations or cancer types. The market for cancer vaccines and monoclonal antibodies is substantial and growing, with new approvals continually expanding the addressable market. Developing a diverse pipeline mitigates risk associated with any single therapeutic approach and increases the probability of bringing a commercial product to market, enhancing long-term value.
• Growth opportunity 4: Commercialization of RhuDex. The development and commercialization of RhuDex for hepatology and gastroenterology indications represents a potential diversification beyond oncology. While currently in development, successful clinical trials and subsequent market approval for RhuDex could open up new revenue streams in distinct therapeutic areas. The global market for hepatology and gastroenterology drugs is significant, driven by the prevalence of chronic liver and digestive diseases. A successful RhuDex program would demonstrate Medigene's capability to develop therapies outside its core oncology focus, potentially attracting new investors and partners interested in these specific medical fields.
• Growth opportunity 5: Geographic Market Expansion. Medigene AG's current operations span Europe, the United States, Asia, and other international markets. Continued strategic expansion into new territories, particularly those with high unmet medical needs and favorable regulatory environments for advanced therapies, could significantly increase its potential patient base and market share. Establishing a stronger presence in key emerging markets or expanding commercial infrastructure in existing regions, potentially through licensing agreements or direct sales forces, would allow Medigene to capitalize on global demand for innovative cancer treatments. This expansion would be particularly impactful upon successful commercialization of its clinical-stage assets.

What Are MDGEF's Competitive Advantages?

• Proprietary T-cell receptor (TCR) technology platform for engineering highly specific T-cell immunotherapies.
• Specialized expertise in T-cell biology, immunology, and personalized medicine for cancer treatment.
• Extensive clinical development pipeline focused on addressing significant unmet medical needs in oncology.
• Strategic partnerships with established biotech firms and leading academic institutions, validating its scientific approach and providing access to resources.
• Intellectual property surrounding its T-cell technologies, dendritic cell vaccines, and monoclonal antibodies, offering protection for its innovations.

What Does MDGEF Do?

Medigene AG, founded in 1994 and headquartered in Munich, Germany, is a biotechnology firm dedicated to advancing T-cell immunotherapies for the treatment of cancer. The company's core therapeutic focus involves the development of personalized T-cell-based treatments, specifically T-cell receptor (TCR)-modified T cells, designed to target and eliminate cancer cells. These innovative therapies are currently in clinical development, representing a significant effort to address substantial unmet medical needs in oncology. Medigene's strategic approach combines cutting-edge research with clinical application, aiming to bring novel therapeutic options to patients. Beyond its primary T-cell immunotherapy work, Medigene is also engaged in researching and developing dendritic cell vaccines, which stimulate the immune system to fight cancer, and T-cell-specific monoclonal antibodies, which can selectively target immune cells or cancer cells. Additionally, the company is involved in the development and commercialization of RhuDex, a compound with potential applications in hepatology and gastroenterology indications, diversifying its therapeutic pipeline. Medigene AG has established several key collaborations to accelerate its research and development efforts. A strategic partnership with 2seventy bio, Inc. focuses on the collaborative advancement of T-cell receptors, leveraging combined expertise to push the boundaries of immunotherapy. Furthermore, the company maintains research collaboration agreements with the Université de Montréal and Cytovant Sciences Co. Ltd., specifically focusing on the identification and validation of novel cancer antigens for immunotherapy applications. With operations and partnerships spanning Europe, the United States, Asia, and other international markets, Medigene AG maintains a global footprint in its pursuit of innovative cancer treatments.

What Products and Services Does MDGEF Offer?

• Develops T-cell receptor (TCR)-modified T cells for personalized cancer immunotherapy.
• Conducts clinical development of innovative T-cell-based treatments for various cancers.
• Researches and develops dendritic cell vaccines to stimulate anti-cancer immune responses.
• Engages in the development of T-cell-specific monoclonal antibodies for targeted therapy.
• Develops and commercializes RhuDex for hepatology and gastroenterology indications.
• Forms strategic partnerships with other biotech and research institutions for collaborative R&D.
• Operates internationally with a focus on Europe, the United States, and Asia.

How Does MDGEF Make Money?

• Primarily generates revenue through strategic partnerships and collaborations, including upfront payments, milestone payments, and potential royalties from licensed technologies.
• Invests heavily in research and development (R&D) to advance its pipeline of T-cell immunotherapies and other therapeutic candidates through preclinical and clinical stages.
• Aims for future commercialization of its proprietary therapies, either independently or through partnerships, following successful regulatory approvals.
• Potentially generates revenue from the development and commercialization of RhuDex in hepatology and gastroenterology.
• Leverages intellectual property and patented technologies to create competitive advantages in the immunotherapy space.

What Industry Does MDGEF Operate In?

Medigene AG operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on immuno-oncology. The global market for cancer immunotherapies is experiencing significant growth, driven by advancements in understanding the immune system's role in fighting cancer and the development of highly targeted treatments. T-cell immunotherapies, including TCR-modified T cells, represent a cutting-edge segment of this market, offering personalized approaches to cancer treatment. Medigene's position is that of a clinical-stage developer, competing with larger pharmaceutical companies and other specialized biotech firms that are also investing heavily in immuno-oncology. The competitive landscape is characterized by intense research and development, high regulatory hurdles, and the need for substantial capital investment. Medigene aims to differentiate itself through its proprietary T-cell receptor platform and strategic collaborations, seeking to carve out a niche in this high-growth, high-risk sector.

Who Are MDGEF's Key Customers?

• Indirectly, patients suffering from various forms of cancer, who will ultimately benefit from successful therapeutic development.
• Pharmaceutical and biotechnology companies seeking to license or partner on innovative T-cell immunotherapy technologies.
• Research institutions and academic collaborators involved in the discovery and validation of novel cancer antigens.
• Healthcare providers and oncologists who would prescribe and administer approved therapies.
• Potentially, patients with hepatology and gastroenterology conditions, if RhuDex achieves commercialization.

Return on equity for Medigene AG stands at -55.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -51.0%, showing how much profit it generates from its asset base. A current ratio of 2.53 indicates the company holds enough short-term assets to cover its near-term obligations.

Medigene AG (MDGEF) Valuation Context

Valued at $38.2M, MDGEF is classified as a micro-cap stock. Relative to its peer group, MDGEF's quantitative score of 48/100 is below the peer average of 76/100.

Company Profile

Medigene AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Martinsried, DE. The company is led by CEO Ralph Schaefer. MDGEF has traded publicly since 2013.

Medigene AG's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.79 places it in the distress zone, a signal of elevated financial risk.

Medigene AG has beaten Wall Street's EPS estimate in 3 of its last 3 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 36.4% above estimates on average.

Wall Street analysts project Medigene AG revenue of about $40.8M for fiscal 2026, with EPS near $-0.98.

MDGEF Financials

MDGEF Latest News

No recent news available for MDGEF.

MDGEF Analyst Consensus

MDGEF MoonshotScore

What Investors Ask About Medigene AG (MDGEF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources